Dublin, Ireland-based Amarin Corporation Plc has raised a net $100.2 million in a secondary offering of its American Depositary Shares, the proceeds of which will be used to support the commercialisation of its lead cardiovascular product, AMR101. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals